Kamada (NASDAQ: KMDA) schedules March 11 call on 2025 results

Rhea-AI Filing Summary

Kamada Ltd. filed a Form 6-K to notify investors that it will release its fiscal year and fourth quarter 2025 financial results on March 11, 2026, before U.S. market open. Management will host an investment community conference call that day at 8:30am Eastern Time.

The notice also highlights Kamada’s focus on specialty plasma-derived therapies for rare and serious conditions, its three plasma collection centers in Texas, and its growth strategy based on organic expansion, in-licensing, plasma collection, and potential mergers and acquisitions.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of March 2026

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

The following exhibit is attached:

99.1 Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

 1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 4, 2026	KAMADA LTD.
	By:	/s/ Nir Livneh
		Nir Livneh Vice President, General Counsel and Corporate Secretary

 2

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

 3

Exhibit 99.1

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel, and HOBOKEN, NJ – March 4, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026.

Kamada’s management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13758519. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1751343&tp_key=e8c73d1516.

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its specialty plasma therapies products portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, including six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two types of equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & MENA through in-licensing partnerships, mainly through the launch of several biosimilar products in Israel. Third, the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

CONTACTS:

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

FAQ

When will Kamada (KMDA) report its fiscal year 2025 financial results?

Kamada will report its fiscal year and fourth quarter 2025 financial results on March 11, 2026. The company plans to release the figures before the U.S. market opens, giving investors time to review the performance ahead of trading that day.

Is Kamada (KMDA) hosting a conference call for the 2025 results?

Yes, Kamada will host a conference call on March 11, 2026 at 8:30am Eastern Time. Management will discuss fiscal year and fourth quarter 2025 results and answer questions from shareholders and other interested parties during the live event.

How can investors access Kamada’s March 11, 2026 earnings call?

Investors can join by dialing 1-877-407-0792 in the U.S., 1-809-406-247 in Israel, or 1-201-689-8263 internationally, using conference ID 13758519. A simultaneous live webcast will be available at the provided Viavid webcasts link.

What is the core business focus of Kamada (KMDA)?

Kamada is a global biopharmaceutical company specializing in plasma-derived therapies for rare and serious conditions. It markets multiple FDA-approved specialty plasma products and aims to grow through organic expansion, in-licensed products, plasma collection, and strategic mergers and acquisitions.

How many plasma collection centers does Kamada currently operate?

Kamada currently operates three plasma collection centers in the United States. These centers are located in Beaumont, Houston, and San Antonio, Texas, supporting the company’s own product demand and sales of normal source plasma to other manufacturers.

Who controls Kamada (KMDA) according to the filing?

The filing states that FIMI Opportunity Funds is Kamada’s controlling shareholder. FIMI beneficially owns approximately 38% of Kamada’s outstanding ordinary shares, reflecting a significant ownership stake in the biopharmaceutical company.

What growth strategies does Kamada outline in this Form 6-K?

Kamada highlights four growth pillars: organic growth of specialty plasma therapies, in-licensing and distribution of third-party drugs in Israel and MENA, expansion of plasma collection operations, and pursuing mergers, acquisitions, and collaborations to enhance its marketed product portfolio.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 KAMADA TO ANNOUNCE FISCAL YEAR AND FOURTH QUARTER 2025 FINANCIAL RESULTS ON MARC 5.9 KB